N-1-Aethylpropyl-N-isopropylamin | 891781-88-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-1-Aethylpropyl-N-isopropylamin
• 英文别名: Isopropyl-pentan-3-yl-amine；N-propan-2-ylpentan-3-amine
• CAS: 891781-88-7
• 化学式: C₈H₁₉N
• mdl: MFCD08437497
• 分子量: 129.246
• InChiKey: ARBUIJSYBRAYHH-UHFFFAOYSA-N

物化性质

• 沸点：
  138.5±8.0 °C(Predicted)
• 密度：
  0.759±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2921199090

反应信息

• 作为反应物：
  描述：

  N-1-Aethylpropyl-N-isopropylamin 、 3,4-二氯苯甲酰氯 生成 3,4-Dichloro-N-(1-ethyl-propyl)-N-isopropyl-benzamide
  参考文献：
  名称：

  Pagani,G. et al., Farmaco, Edizione Scientifica, 1978, vol. 33, p. 531 - 542

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氨基戊烷 、 alkaline earth salt of/the/ methylsulfuric acid 生成 N-1-Aethylpropyl-N-isopropylamin
  参考文献：
  名称：

  Baruffini; Vicarini; Gandini, Farmaco, Edizione Scientifica, 1978, vol. 33, # 7, p. 522 - 530

  摘要：

  DOI：

文献信息

• PYRROLOTRIAZINE KINASE INHIBITORS
  申请人：Fink E. Brian

  公开号：US20080045496A1

  公开（公告）日：2008-02-21

  The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of such as TrkA, TrkB, TrkC, Jak2, Jak3 and CK2, thereby making them useful as antiproliferative agents for the treatment of cancer and other diseases.

  本发明提供了公式I的化合物以及药用可接受的盐类。公式I的化合物可以抑制诸如TrkA、TrkB、TrkC、Jak2、Jak3和CK2的酪氨酸激酶活性，从而使其作为抗增殖剂用于治疗癌症和其他疾病的有用性。
• Selective Palladium(II)-Catalyzed Carbonylation of Methylene β-C−H Bonds in Aliphatic Amines
  作者：Jaime R. Cabrera-Pardo、Aaron Trowbridge、Manuel Nappi、Kyohei Ozaki、Matthew J. Gaunt

  DOI：10.1002/anie.201706303

  日期：2017.9.18

  The ligand is key: Palladium(II)-catalyzed C−H carbonylation reactions of methylene C−H bonds in secondary aliphatic amines lead to the formation of trans-disubstituted β-lactams in excellent yields and selectivities. The generality of the C−H carbonylation process is aided by the action of xantphos-based ligands.

  配体是关键：钯（II）催化的脂肪族仲胺中亚甲基CH键的CH羰基化反应导致反式二取代的β-内酰胺的形成，具有极高的收率和选择性。基于Xantphos的配体的作用有助于CH羰基化过程的普遍性。
• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：Universal Display Corporation

  公开号：US20210040129A1

  公开（公告）日：2021-02-11

  Provided are a compound of formula Ir(L A ) x (L B ) y (L C ) z wherein L A has

  提供的是一个化合物的公式 Ir(LA)x(LB)y(LC)z，其中LA为
• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。